A5056289058- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Advanced Radiotherapy Techniques
- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Urologic and reproductive health conditions
- Advances in Oncology and Radiotherapy
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Medical Imaging Techniques and Applications
- Effects of Radiation Exposure
- Cancer survivorship and care
- Colorectal Cancer Surgical Treatments
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Endometrial and Cervical Cancer Treatments
- Esophageal Cancer Research and Treatment
- Management of metastatic bone disease
- Hormonal and reproductive studies
- Health Systems, Economic Evaluations, Quality of Life
- Carcinogens and Genotoxicity Assessment
- Statistical Methods in Clinical Trials
- Hepatocellular Carcinoma Treatment and Prognosis
University Hospital Ulm
2014-2024
Klinik und Poliklinik für Strahlentherapie und Radioonkologie
2001-2024
Universität Ulm
2014
Technical University of Munich
2001-2012
Klinikum rechts der Isar
2003-2011
Universitätsklinik für Strahlentherapie
2003-2009
Ludwig-Maximilians-Universität München
2002-2004
Stereotactic Radiotherapy has the potential to produce high local control rates with low risk of severe lung toxicity. From December 2000 January 2006, 68 inoperable patients (median age 76 years) stage I NSCLC received definitive hSRT. A mean total dose 37.5 Gy (24–40 Gy; 60%-isodose) in 3–5 fractions was applied. Immobilisation carried out by means a vacuum couch and pressure foil (Medical Intelligence, Schwab München, Germany). Staging procedures were thoracic abdominal CT-scan, FDG-PET...
Abstract Purpose 68 Ga-PSMA-11-PET/CT is increasingly used in early-stage biochemical recurrence of prostate cancer to detect potential lesions for an individualized radiotherapy concept. However, subtle findings especially concerning small local recurrences can still be challenging interpret and are prone variability between different readers. Thus, we analyzed interobserver variability, detection rate, lesion patterns systematically a homogeneous patient population with low-level...
Radiotherapists are highly interested in optimizing doses especially for patients who tend to suffer from side effects of radiotherapy (RT). It seems be helpful identify radiosensitive individuals before RT. Thus we examined aberrations FISH painted chromosomes vitro irradiated blood samples a group suffering breast cancer. In parallel, follow-up these was registered and compared detected chromosome aberrations.Blood (taken radiotherapy) were with 3 Gy X-rays analysed by FISH-painting obtain...
For patients with recurrent prostate cancer after radical prostatectomy (RP), salvage radiotherapy (SRT) is a second chance of cure. However, depending on risk factors, 40-70% the experience further progression. With focus pre- and post-SRT serum level prostate-specific antigen (PSA), we assessed determinants long-term outcome SRT.Between 1997 2011, 464 received 3D-conformal SRT median 66.6 Gy. The PSA before was 0.31 ng/ml. In our retrospective analysis, progression defined as either rising...
The new Medical Licensing Regulations 2025 (Ärztliche Approbationsordnung, ÄApprO) will soon be passed by the Federal Council (Bundesrat) and implemented step individual faculties in coming months. further development of medical studies essentially involves an orientation from fact-based to competence-based learning focuses on practical, longitudinal interdisciplinary training. Radiation oncology radiation therapy are important components therapeutic great importance for public health, both...
Salvage radiotherapy (SRT) improves oncologic outcomes in prostate cancer (PCa) patients who develop biochemical recurrence (BCR) after radical prostatectomy (RP). However, evidence on hard clinical endpoints is scarce. We compare long-term of SRT versus no (noRT) with BCR RP.Within a multi-institutional database, we identified RP between 1989 and 2016 for PCa. Patients lymph node invasion, adjuvant radiotherapy, or additional androgen deprivation therapy at were excluded. In all SRT, was...
The European Association of Urology (EAU) proposed a risk stratification (high vs. low risk) for patients with biochemical recurrence (BR) following radical prostatectomy (RP). Here we investigated whether this accurately predicts outcome, particularly in staged PSMA-PET.